No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Molecular Markers
January 27, 2021
An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
November 21, 2020
A scholarly and sober narrative review on , as the authors state, a ' hot topic' that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
November 7, 2019
This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with advanced lung cancer.
May 10, 2019
Patient Care and General Interest
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was a marker for patient selection for immunotherapy.
May 30, 2018
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.
May 23, 2018
This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to
December 13, 2017
Liquid biopsies have long held promise for diagnosis, treatment selection, and surveillance of lung cancer patients. This articles summarizes results of two studies involving highly precise measurement of tumor mutational burden. A burden of 16-fold or greater was associated with improved overall survival with immunotherapy (atezolizumab) compared
October 31, 2017
In this single institution study, the authors screened biorepository materials obtained from patients undergoing resection for early stage cancer. They wished to identify serum markers related to early recurrence. A 7-component panel was developed that had a negative predictive value of 83% and an accuracy of 78%. The accuracy was 70%.